PMID- 32590982
OWN - NLM
STAT- MEDLINE
DCOM- 20201026
LR  - 20201026
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 19
IP  - 1
DP  - 2020 Jun 26
TI  - SGLT2i: beyond the glucose-lowering effect.
PG  - 98
LID - 10.1186/s12933-020-01071-y [doi]
LID - 98
AB  - Sodium/glucose cotransporter-2 inhibitors (SGLT2i) are a new type of 
      glucose-lowering drug that can reduce blood glucose by inhibiting its 
      reabsorption in proximal tubules and by promoting urinary glucose excretion. 
      SGLT2i are widely used in the clinical treatment of type 2 diabetes mellitus 
      (T2DM). In recent studies, SGLT2i were found to not only reduce blood glucose but 
      also protect the heart and kidney, which can significantly reduce cardiovascular 
      events, delay the progression of renal failure, greatly improve the quality of 
      life of patients, and reduce medical expenses for families and society. As 
      adverse cardiac and renal events are the most common and serious complications of 
      T2DM, it is very important to understand the cardio- and renoprotective 
      mechanisms of SGLT2i. This article reviews the historical development, 
      pharmacological mechanism, heart and kidney protection and safety of SGLT2i. The 
      information presented provides a theoretical basis for the clinical prevention 
      and treatment of diabetes and its complications and for the development of new 
      glucose-lowering drugs.
FAU - Ni, Lihua
AU  - Ni L
AD  - Department of Nephrology, Zhongnan Hospital of Wuhan University, 169 Donghu Road, 
      Wuhan, Hubei, 430071, China.
FAU - Yuan, Cheng
AU  - Yuan C
AD  - Department of Gynecological Oncology, Zhongnan Hospital, Wuhan University, Wuhan, 
      430071, People's Republic of China.
FAU - Chen, Guopeng
AU  - Chen G
AD  - Institute of Model Animal, Wuhan University, Wuhan, 430071, China.
AD  - School of Basic Medical Sciences, Wuhan University, Wuhan, 430071, China.
FAU - Zhang, Changjiang
AU  - Zhang C
AD  - Department of Cardiology, Renmin Hospital of Wuhan University, Zhang Road No. 99, 
      Wuhan, Hubei, 430060, China. zcj2008@163.com.
AD  - Cardiovascular Research Institute, Wuhan University, Wuhan, 430060, People's 
      Republic of China. zcj2008@163.com.
AD  - Hubei Key Laboratory of Cardiology, Wuhan, 430060, People's Republic of China. 
      zcj2008@163.com.
AD  - Cardiovascular Disease Center, Enshi Central Hospital, Enshi, 445000, People's 
      Republic of China. zcj2008@163.com.
FAU - Wu, Xiaoyan
AU  - Wu X
AD  - Department of Nephrology, Zhongnan Hospital of Wuhan University, 169 Donghu Road, 
      Wuhan, Hubei, 430071, China. wuxiaoyan_kid@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200626
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Animals
MH  - Biomarkers/blood
MH  - Blood Glucose/*drug effects/metabolism
MH  - Cardiovascular Diseases/diagnosis/epidemiology/physiopathology/*prevention & 
      control
MH  - Cardiovascular System/*drug effects/physiopathology
MH  - Diabetes Mellitus, Type 2/blood/diagnosis/*drug therapy/epidemiology
MH  - Diabetic Nephropathies/diagnosis/epidemiology/physiopathology/*prevention & 
      control
MH  - Down-Regulation
MH  - Humans
MH  - Kidney/*drug effects/physiopathology
MH  - Renal Insufficiency/diagnosis/epidemiology/physiopathology/*prevention & control
MH  - Risk Assessment
MH  - Risk Factors
MH  - Sodium-Glucose Transporter 2 Inhibitors/adverse effects/*therapeutic use
MH  - Treatment Outcome
PMC - PMC7320582
OTO - NOTNLM
OT  - Cardiovascular disease
OT  - Renal disease
OT  - Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
OT  - Type 2 diabetes
COIS- The authors declare that they have no competing interests.
EDAT- 2020/06/28 06:00
MHDA- 2020/10/27 06:00
PMCR- 2020/06/26
CRDT- 2020/06/28 06:00
PHST- 2020/04/04 00:00 [received]
PHST- 2020/06/16 00:00 [accepted]
PHST- 2020/06/28 06:00 [entrez]
PHST- 2020/06/28 06:00 [pubmed]
PHST- 2020/10/27 06:00 [medline]
PHST- 2020/06/26 00:00 [pmc-release]
AID - 10.1186/s12933-020-01071-y [pii]
AID - 1071 [pii]
AID - 10.1186/s12933-020-01071-y [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2020 Jun 26;19(1):98. doi: 10.1186/s12933-020-01071-y.